Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977780 · ClinicalTrials.gov registry record · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
A Phase 2 study of Glioblastoma, sponsored by Patrick Wen, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
- 12
- Study locations
NCT02977780: Recruiting Phase 2 study of Glioblastoma, sponsored by Patrick Wen, MD.
NCT02977780 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Patrick Wen, MD. The registered enrollment target is 460 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (330% higher). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02977780, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Patrick Wen, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Temozolomide
- DRUG Abemaciclib
- DRUG QBS10072S
- DRUG CC-115
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Rhode Island
- Lifespan / Rhode Island Hospital - Providence
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
What NCT02977780 shows while recruiting
NCT02977780 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (330% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Neratinib is the first listed.
NCT02977780 lists 12 locations in 10 states (Massachusetts, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT02977780 about?
NCT02977780 is a clinical study titled "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)". This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currentl...
What is the current status of trial NCT02977780?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2017-02-09. Estimated completion is 2028-04-30.
What conditions does trial NCT02977780 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02977780?
The interventions under investigation include: Neratinib (DRUG), Temozolomide (DRUG), Abemaciclib (DRUG), QBS10072S (DRUG), CC-115 (DRUG).
Who is sponsoring clinical trial NCT02977780?
This trial is sponsored by Patrick Wen, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977780 being conducted?
This trial has 12 study locations across Alabama, Massachusetts, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02977780's enrollment target sits among peer trials
460 12th of 199 higher than 188 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
- NCT05123482 · 460 participants · Phase 1
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI